Gilead Sciences Canada Announces Phase 3 PURPOSE 1 Trial Results; Lenacapavir Shows 100% Efficacy in HIV Prevention for Cisgender Women; Data Monitoring Committee Recommends Offering Open-Label Lenacapavir to All Participants
Gilead Sciences Canada Announces Phase 3 PURPOSE 1 Trial Results; Lenacapavir Shows 100% Efficacy in HIV Prevention for Cisgender Women; Data Monitoring Committee Recommends Offering Open-Label Lenacapavir to All Participants
吉利德科學加拿大宣佈3期PURPOSE 1試驗結果：Lenacapavir對非跨性別女性HIV預防的功效達100%；數據監測委員會建議向所有參與者提供開放式Lenacapavir。
– First Phase 3 HIV Prevention Trial to Show Zero Infections –
——第一階段3項HIV預防試驗未發生感染——
– Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim Analysis and Offer Open-Label Lenacapavir to All Participants –
——獨立數據監管委員會建議吉利德在中期分析中停止PURPOSE 1試驗中的盲區階段，並向所有參與者提供開放式Lenacapavir
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。